Smruthi Organics Ltd.
Snapshot View

354.30 +9.40 ▲2.7%

23 July 2021, 04:00:00 P.M.
Volume: 37,743

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.smruthiorganics.com
Financial Indicators
Market Cap 405.54 Cr.
Earnings per share (EPS) 14.55 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 24.35 Trailing Twelve Months Ending 2021-06
Industry PE 35.17 Trailing Twelve Months Ending 2021-06
Book Value / Share 55.06 Trailing Twelve Months Ending 2021-06
Price to Book Value 6.43 Calculated using Price: 354.30
Dividend Yield 0.85 Period Ending 2021-03
No. of Shares Subscribed 1.14 Cr. 11,446,290 Shares
FaceValue 10
Company Profile
Smruthi Organics Ltd is a mid-size, public limited, API manufacturing company from Solapur, India. Smruthi Organics Ltd was established in1989 by qualified technocrats and has very good experience and reputation in the pharmaceutical industry for the supply of quality products. 

Their core competency is multi-step organic synthesis and large scale manufacturing of organic molecules. Their focus has always been API for the regulated markets. They have been part of successful contract manufacturing and custom synthesis agreements with leading European, American and Japanese customers. They are currently expanding our R&D to become a one-stop solution provider from concept to execution for all API including, but not restricted to, the following: 
  • Process Development
  • Process Optimization
  • Process Validation
  • Analytical Methods Validation
  • Regulatory Support and DMF Registrations
  • Commercial Manufacturing

Their constant endeavor to improve operations and systems has contributed to our growth. they encourage operational transparency with customers, which complements to confidence building for stronger relationships. Customer satisfaction is their highest priority and they constantly strive on optimizing delivery times of all their services.

Smruthi Organics Ltd facility is USFDA approved and European GMP certified for Carbidopa, Metformin HCL and Norfloxacin. It has successfully filed 4 European and US drug master files for different products.

Smruthi can manage a potential molecule's entire development life cycle up to commercialization through rigorous planning and proper execution. Smruthi can independently or in conjunction with the customer develop optimized synthesis process, perform scale-up and process validations, compile DMF and provide the customer with regulatory support for finished formulation dossier registration. The engagement can be either on an FTE or deliverables basis. We respect absolute confidentiality in such sensitive relationships enhancing smooth exchange of information.

Product range of the company includes:

API   
  • Amlodipine Base
  • Amlodipine Besilate
  • Carbidopa
  • Carvedilol
  • Chlorhexidine Base
  • Chlorhexidine Salts
  • Ciprofloxacin HCI
  • Clofibrate
  • Diloxanide Furoate
  • Enrofloxacin
  • Fenofibrate
  • Fluconazole
  • Iopomidol
  • Metformin HCI
  • Norfloxacin
  • Pefloxacin
  • S-Amlodipine
  • Nabumetone
Drug Intermediate
  • Nabumetone
  • Iopamidol / Iohexol
  • Montelukast
  • Iopamidol
  • Co-enzyme Q10
  • Atorvastatin
  • Carvedilol
  • Ciprofloxacin/Enrofloxacin
  • Perindopril
Achievements/ recognition:
  • The company’s quality systems and facilities are approved by USFDA, EU – GMP and ISO 9001:2000. 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.73%
1 Week
-6.63%
1 Month
+7.04%
3 Month
+44.02%
6 Month
+84.53%
1 Year
+648.57%
2 Year
+730.33%
5 Year
+664.07%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 16.51 -16.15 -11.83 2.41 5.03 -10.48 20.97 21.43 33.23
Return on Capital Employed (%) 18.11 -4.60 -0.01 9.53 10.60 -0.96 21.54 25.00 39.14
Return on Assets (%) 5.15 -4.83 -3.27 0.69 1.69 -3.79 7.42 8.96 19.05

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 41 35 29 31 32 29 36 42 60
Non Curr. Liab. 22 32 34 32 11 7 7 7 7
Curr. Liab. 66 58 44 39 42 48 57 38 25
Minority Int.
Equity & Liab. 129 126 107 102 85 84 101 88 92
Non Curr. Assets 46 67 61 58 41 33 36 35 33
Curr. Assets 82 59 47 44 44 51 65 53 59
Misc. Exp. not W/O
Total Assets 129 126 107 102 85 84 101 88 92

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 181 94 77 74 79 97 137 131 127
Other Income 0 1 0 0 1 0 1 4 1
Total Income 182 94 77 74 80 98 138 136 127
Total Expenditure -162 -92 -72 -63 -69 -94 -121 -116 -98
PBIDT 19 2 5 11 11 3 17 20 29
Interest -4 -5 -6 -5 -4 -4 -4 -3 -1
Depreciation -5 -6 -5 -4 -4 -4 -4 -4 -4
Taxation -4 3 2 -1 -1 1 -3 -4 -7
Exceptional Items
PAT 6 -6 -4 1 2 -3 7 8 17

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 5 9 9 14 9 5 12 21 23
Cash Fr. Inv. -13 -2 -1 0 0 -3 -5 -5 -3
Cash Fr. Finan. 6 -6 -8 -14 -9 -2 -5 -17 -7
Net Change -1 2 -1 0 0 0 2 -1 13
Cash & Cash Eqvt 1 2 2 2 2 2 4 4 16

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 63.83 63.83 63.83 63.83 63.83 63.97 63.50 63.39 63.39
Public 36.17 36.17 36.17 36.17 36.17 36.03 36.50 36.61 36.61
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement- Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Sat, 17 Jul 2021
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)
Smruthi Organics Ltd has informed BSE regarding the details of Voting results of AGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here
Fri, 16 Jul 2021
(I) The Unaudited Financial Results For The First Quarter Ended 30Th June 2021.; And (Ii) Limited Review Report Dated 16Th July 2021
Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Friday 16th July 2021 ("said meeting") considered and approved the Unaudited Financial Results of the Company for the first quarter ended 30thJune 2021.
Further pursuant to the applicable provisions of SEBI Listing Regulations please find enclosed herewith: - (i) the Unaudited Financial Results; and (ii) Limited Review Report dated 16th July 2021 issued by the Statutory Auditors of the Company w.r.t. the Unaudited Financial Results and taken on record by the Board of Directors of the Company.

Technical Scans View Details

Fri, 23 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
MACD Crossing Signal Line From Above MACD Crossing Signal Line From Above
Thu, 22 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%